NORTHLAND’s patent wins the China Patent Excellence Award.

Category:

2015-12-18


On December 15, 2015, the 17th China Patent Award Ceremony was held at the National Intellectual Property Administration. Our company’s invention patent, “Thymosin β4 Derivatives and Their Applications” (Patent No. ZL200680025339.0), was awarded the “China Patent Excellence Award” by the National Intellectual Property Administration. Nie Liya, Executive Deputy General Manager of the company, attended the award ceremony.

Recombinant human thymosin β4 is a therapeutic biological product developed by our company, which can be used to develop medications for indications including skin injuries, corneal injuries, dry eye syndrome, and myocardial infarction. This project has received continuous support from the national “11th Five-Year Plan” and “12th Five-Year Plan” major science and technology programs for the creation of new drugs, and successfully completed technology transfer to South Korea in 2015.

 

 

 

Share to: